Published in J Neural Transm Suppl on January 01, 1998
Visuo-motor coordination deficits and motor impairments in Parkinson's disease. PLoS One (2008) 0.87
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology (2008) 3.83
Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM (1996) 2.54
Effect of polyoxin D on chitin synthesis and septum formation in Saccharomyces cerevisiae. J Bacteriol (1974) 2.50
A phenylethylamine oxidising defect in migraine. Nature (1974) 2.28
Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease. Eur J Neurol (2003) 2.17
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Correlating a protein structure with function of a bacterial mechanosensitive channel. J Biol Chem (2000) 1.92
Conjugation defect in tyramine-sensitive migraine. Nature (1971) 1.91
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89
Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait. Exp Brain Res (2003) 1.88
Technique factors and image quality as functions of patient weight at abdominal CT. Radiology (2000) 1.80
Multiple forms of rat brain monoamine oxidase. Nature (1969) 1.77
Gait instability and fractal dynamics of older adults with a "cautious" gait: why do certain older adults walk fearfully? Gait Posture (2005) 1.77
Properties of purified, soluble monoamine oxidase. Can J Biochem (1966) 1.76
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
Bilateral coordination of gait and Parkinson's disease: the effects of dual tasking. J Neurol Neurosurg Psychiatry (2009) 1.70
The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology (2007) 1.70
Globus pallidus internus pallidotomy for generalized dystonia. Mov Disord (1997) 1.69
Multiple forms of human brain mitochondrial monoamine oxidase. Nature (1970) 1.69
Deprenyl in Parkinson's disease. Lancet (1977) 1.66
Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors. J Neurol (2005) 1.63
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm (1975) 1.62
Multiple forms of monoamine oxidase: functional significance. Pharmacol Rev (1972) 1.56
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem (1994) 1.46
Quantitative anal sphincter EMG in multisystem atrophy and 100 controls. J Neurol Neurosurg Psychiatry (2001) 1.42
Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am J Psychiatry (2000) 1.42
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet (1977) 1.38
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol (1975) 1.38
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33
Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem (2001) 1.30
Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect (1990) 1.27
An instrumented timed up and go: the added value of an accelerometer for identifying fall risk in idiopathic fallers. Physiol Meas (2011) 1.26
Effect of iron chelators on dopamine D2 receptors. J Neurochem (1985) 1.22
Relationship between freezing of gait (FOG) and other features of Parkinson's: FOG is not correlated with bradykinesia. J Clin Neurosci (2003) 1.20
Promotion of 4-hydroxy-3-methoxyphenylglycol formation in man by reserpine. Nature (1968) 1.19
Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl (1997) 1.16
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol (1991) 1.13
Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord (2001) 1.13
Endothelial cells from bovine adrenal medulla develop capillary-like growth patterns in culture. Proc Natl Acad Sci U S A (1985) 1.11
Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol (1995) 1.11
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett (1994) 1.10
Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol (1977) 1.10
Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol (2004) 1.09
Treadmill training for the treatment of gait disturbances in people with Parkinson's disease: a mini-review. J Neural Transm (Vienna) (2008) 1.09
Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature (1972) 1.09
Subjective memory complaints in elders: depression, anxiety, or cognitive decline? Acta Neurol Scand (2012) 1.08
The binding of (14C)phenethylhydrazine to rat liver monoamine oxidase. Biochem Pharmacol (1975) 1.08
Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem (1996) 1.07
The metabolism of 5-hydroxytryptamine and beta-phenylethylamine in perfused rat lung and in vitro. Br J Pharmacol (1979) 1.07
Physicochemical properties, development, and regulation of central and peripheral monoamine oxidase activity. Adv Biochem Psychopharmacol (1974) 1.07
Phosphorylation by protein kinase A of RCK1 K+ channels expressed in Xenopus oocytes. Biochemistry (1994) 1.05
The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm (Vienna) (2005) 1.05
LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics (2009) 1.05
On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm (1978) 1.05
Effect of implementation of safety measures in tae kwon do competition. Br J Sports Med (2003) 1.04
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem (1992) 1.04
The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem (1991) 1.04
Decreased monoamine oxidase activity in liver of iron-deficient rats. Can J Biochem (1969) 1.03
Hand rhythmic tapping and timing in Parkinson's disease. Parkinsonism Relat Disord (2004) 1.02
Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem (2001) 1.01
Asbestotic radiological abnormalities among United States merchant marine seamen. Br J Ind Med (1990) 1.01
Heterogeneity of rat brain mitochondrial monoamine oxidase. Adv Biochem Psychopharmacol (1974) 1.00
The oestrous cycle and monoamine oxidase activity. Br J Pharmacol (1973) 0.99
Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol (1981) 0.99
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem (1986) 0.98
Brain iron: a lesson from animal models. Am J Clin Nutr (1989) 0.98
Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem (1991) 0.98
Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med (1979) 0.98
The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa. Metabolism (1992) 0.97
[Botulinum toxin as a powerful new tool in the treatment of focal dystonia]. Harefuah (1991) 0.96
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol (2001) 0.96
Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol (1981) 0.96
Differential phenotype in Parkinson's disease patients with severe versus mild GBA mutations. Brain (2009) 0.96
Nutritional iron and dopamine binding sites in the rat brain. Pharmacol Biochem Behav (1982) 0.96
Proceedings: Substrate and strain-dependent differences in the development of monoamine oxidase in the rat brain. Br J Pharmacol (1975) 0.96
Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta (1996) 0.95
The challenge of evaluating freezing of gait in patients with Parkinson's disease. Br J Neurosurg (2008) 0.94
Metabolism of phenylethylamine in rat isolated perfused lung: evidence for monoamine oxidase 'type B' in lung. Br J Pharmacol (1976) 0.94
Tetrabenazine treatment in movement disorders. Clin Neuropharmacol (2004) 0.94
A wearable system to assist walking of Parkinson s disease patients. Methods Inf Med (2009) 0.94
Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. Ann N Y Acad Sci (2000) 0.93
Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J Neurochem (1996) 0.93
The effect of yohimbine on brain serotonin metabolism, motor behavior and body temperature of the rat. Eur J Pharmacol (1971) 0.93
Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem (1991) 0.93
The influence of tissue environment on the rates of metabolic processes and the properties of enzymes. Biochem Pharmacol (1975) 0.92
5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats. Br J Pharmacol (1985) 0.92
Irreversible ototoxic effect of erythromycin. Scand Audiol (1986) 0.92
Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm (Vienna) (2004) 0.92
Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J Neurochem (1995) 0.92
Impaired iron homeostasis in Parkinson's disease. J Neural Transm Suppl (2000) 0.91
The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations. Neurology (2001) 0.91
Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Adv Neurol (1987) 0.91
A two-year follow-up evaluation of acute psychotic patients treated in a day hospital. Am J Psychiatry (1966) 0.91
Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm (Vienna) (2001) 0.90
Pharmacology of selegiline. Neurology (1996) 0.90